Morepen Labs shares jump 5%, snap eight-day losing streak on US generic drug market foray
CNBC-TV18

Morepen Labs shares surged five percent, ending an eight-day losing streak after entering the United States generic drug market.
Morepen Labs shares climbed five percent to break an eight-day losing streak following the company's new venture into the US generic drug market. While Morepen has previously supplied Desloratadine Active Pharmaceutical Ingredients to the United States for years, this latest development marks its official entry into finished-dosage medicines and distribution within the country.
Why it matters: The move expands Morepen Labs' business model in the United States from supplying raw ingredients to distributing finished-dosage medicines, directly impacting its market performance.








